Τόμος 23 (2009) – Τεύχος 2 – Άρθρο 9 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 23 (2009) – Issue 2 – Article 9 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

A’ Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki

pharmakonpress[at]pharmakonpress[.]gr

2. Gomez-Sanchez E.P.: Central hypertensive effects of aldosterone. Front. Neuroendocrinol. 18: 440-462 (1997)

3. Hostetter T.H., Ibrahim H.N.: Aldosterone in chronic kidney and cardiac disease. J. Am. Soc. Nephrol. 14: 2395-2401 (2003)

4. Ruggenenti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., Scolari F., Schena F.P., Remuzzi G.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364 (1999)

5. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N. Engl. J. Med. 329: 1456-1462 (1993)

6. GISEN Group: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 359: 1857-1863 (1997)

7. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S.; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345: 861-869 (2001)

8. Weber K.T., Brilla C.G.: Myocardial fibrosis and the renin-angiotensin-aldosterone system. J. Cardiovasc. Pharmacol. 20: S48-S54 (1992)

9. Greene E.L., Kren S., Hostetter T.H.: Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98: 1063-1068 (1996)

10. Quan Z.Y., Walser M., Hill G.S.: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 41: 326-333 (1992)

11. Rocha R., Chander P.N., Zuckerman A., Stier C.T. Jr.: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237 (1999)

12. Rocha R., Stier C.T. Jr., Kifor I., Ochoa-Maya M.R., Rennke H.G.,Williams G.H., Adler G.K.: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878 (2000)

13. Walker W.G.: Hypertension related injury: A major contributor to end-stage renal disease. Am. J. Kidney Dis. 22: 164-173 (1993)

14. Ciraku I., Kailasam M., O’Conner D., Parmer R.: Renal aldosterone excretion predicts early renal injury in human essential hypertension [Abstract]. J. Am. Soc. Nephrol. 11: 345 (2000)

15. Chrysostomou A., Becker G.: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. 345: 925-926 (2001)

16. Sato A., Hayashi K., Naruse M., Saruta T.: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64-68 (2003)

17. Epstein M., Buckalew V., Altamirano J. et al.: Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction. J. Am. Coll. Cardiol. 39(Suppl. 1): 119 (2002)

18. Wakisaka M., Spiro M.J., Spiro R.G.: Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 43: 95-103 (1994)

19. Juknevicius I., Segal Y., Kren S., Lee R., Hostetter T.H.: Aldosterone causes TGF-β expression [Abstract]. J. Am. Soc. Nephrol. 11: 622 (2000)

20. Myronidou M., Kokkas B., Kouyoumtzis A., Gregoriadis N., Lourbopoulos A., Mylonas I., Papadopoulos P.C., Papadopoulos C.L., Mirtsou-Fidani V.: Losartan increases NO production from the bovine aortic wall that is stimulated by angiotensin II. Eur. J. Inflam. 1: 113-117 (2003)

21. Farquharson C.A., Struthers A.D.: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. (Lond). 103: 425-431 (2002)

22. Campese V.M., Bianchi S., Bigazzi R.: Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr. Opin. Nephrol. Hypertens. 9: 143-147 (2000)

23. Funder J.W.: Eplerenone, a new mineralocorticoid antagonist: In vitro and in vivo studies. Curr. Opin. Endocrinol. Diabetes 7: 138-142 (2000)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr